A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

Inclusion Criteria:

- Diagnosis of metastatic Stage IV NSCLC

- At least 1 measurable extra-central nervous system (CNS) lesion

- Documented radiographic progression while on continuous treatment with erlotinib
monotherapy

- Objective clinical benefit from erlotinib treatment as defined by either documented
partial or complete response or stable disease ≥6 months or, if most recent erlotinib
treatment has been initiated based on documented epidermal growth factor receptor
mutation (EGFRmt) status, at least 12 weeks stable disease

- Determined to be MET diagnostic positive (+)

- Availability of a tumor sample post-erlotinib progression

- Eastern Cooperative Oncology Group (ECOG) performance status ≤2

- Have adequate organ function

Exclusion Criteria:

- Are currently enrolled in, or discontinued within the last 30 days from, a clinical
trial involving an investigational product or non-approved use of a drug or device

- Have previously been treated with LY2875358 or any other MET-targeting experimental
therapeutic

- Have a serious concomitant systemic disorder or significant cardiac disease

- Have interstitial pneumonia or interstitial fibrosis of the lung or have pleural
effusion, pericardial fluids or ascites, requiring drainage every other week or more
frequently

- Have a history of another malignancy except for basal or squamous cell skin cancer
and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and
without evidence of recurrence for at least 3 years prior to the study

- Have major surgery less than 2 weeks prior initiation of study treatment therapy

- Pregnant or lactating women

- Have symptomatic CNS metastasis